Is Xanax bad for your kidneys? (3+ guidelines)
By
Dr Drielli Vital-Fujii (PhD)
Author bio
Dr Drielli Vital-Fujii, PhD, is a Pharmacist with expertise in Drug Design and Development, Enzymes, Molecular Modelling, and Photodynamic Therapy. She writes and reviews content on these topics.
Dr Drielli Vital-Fujii’s Highlights:
- Postdoctoral fellow at the Department of Biochemistry at the University of São Paulo, emphasizing therapy of neglected diseases using light.
- PhD in Pharmaceutical Sciences focusing on drug design and development at the Faculty of Pharmaceutical Sciences of the University of São Paulo.
- Six months as an international researcher at the Center for Discovery and Innovation in Parasitic Diseases (University of California San Diego)
- Master’s degree in Pharmaceutical Sciences focusing on drug design and development at the Faculty of Pharmaceutical Sciences of the University of São Paulo.
- Bachelor of Pharmacy at the University of Mogi das Cruzes – São Paulo / Brazil
Professional Experience:
2012 – 2018 Project manager at University of São Paulo – Pharmacy Department
Dr Drielli Vital-Fujii has worked with computational studies, synthesis, biological evaluation, design, and development of new inhibitor candidates for Chagas Disease and Leishmaniasis.
2017 – 2017 International research fellow at University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences – Center for Discovery and Innovation in Parasitic Diseases.
She used Virtual Screening (VS) and High-Throughput Screening (HTS) Integration in the Discovery of new drugs against neglected tropical diseases (NTDs).
2018 – 2019 Faculdades Oswaldo Cruz
Dr Drielli Vital-Fujii was a professor in the Faculty of Pharmacy, teaching the subjects of Pharmaceutical Chemistry and Drug Development.
2019 – 2021 Researcher in Biochemistry University of São Paulo – Biochemistry Department
She applied Photodynamic Therapy in Leishmaniasis Treatment, mentored undergraduate students in scientific activities, and wrote, executed, translated, and reported scientific projects with funding agencies.
2023-2023 UniPiaget – University Center.
Dr Drielli Vital-Fujii was a Biology, Nutrition, Physiotherapy, and Pharmacy professor.
Education:
2018 -2021 Postdoctoral at the Department of Biochemistry at the University of São Paulo
2013 -2018 PhD of Science: Drugs and Medicines at Department of Pharmacy at University of São Paulo
2012 -2013 M.Sc. of Sciences: Drugs and Medicines at the Department of Pharmacy at the University of São Paulo
2005-2008 Bachelor of Pharmacy at the University of Mogi das Cruzes
The leading publications of Dr Drielli Vital-Fujii are:
Vital-Fujii, D.G, Baptista, M.S. (2021). Progress in the photodynamic therapy treatment of Leishmaniasis. Brazilian Journal of Medical and Biological Research, 54, 1-11.
Gatti, F. M., Gomes, R.A., da Fonseca, A.L., Lima, E.J.C., Vital-Fujii, D.G., Taranto, A.G., Varotti, F.P., Trossini, G.H.G. (2020). Antiplasmodial activity of sulfonylhydrazones: in vitro and in silico approaches. Future medicinal chemistry, 13, 233-250.
Silva, E.J., Bezerra-Souza, A., Passero, L.F., Laurenti, M.D., Ferreira, G.M., Fujii, D.G.V., et al. (2018). Synthesis, leishmanicidal activity, structural descriptors and structure-activity relationship of quinoline derivatives. Future medicinal chemistry, 10, 2069-2085.
Leite, F.H.A., Froes, T.Q., da Silva, S.G., de Souza, E.I.M., Vital-Fuji,i D.G., Trossini, G.H.G., et al. (2017). An integrated approach towards the discovery of novel non-nucleoside Leishmania major pteridine reductase 1 inhibitors. European Journal of Medicinal Chemistry, 132, 322-332.
Vital, D.G., Damasceno, F.S., Rapado, L.N., Silber, A.M., Vilella, F.S., Ferreira, R.S., et al. (2017). Application of bioisosterism in design of the semicarbazone derivatives as cruzain inhibitors: a theoretical and experimental study. Journal of Biomolecular Structure and Dynamics, 35, 1244–1259.
Mello, J. F.R., Gomes, R.A., Vital-Fujii, D.G., Ferreira, G.M., Trossini, G.H.G. (2017). Fragment-based drug discovery as alternative strategy to the drug development for neglected diseases. Chemical Biology & Drug Design, 90, 1067-1078.
Pantaleao, S.Q., Fujii, D.G.V., Maltarollo, V.G., da C. Silva, D., Trossini, G.H.G., Weber, K.C., et al. (2017). The Role of QSAR and Virtual Screening Studies in Type 2 Diabetes Drug Discovery. Medicinal Chemistry, 13, 706-720.
Vital, D., Arribas, M., Trossini, G. (2014). Molecular Modeling and Docking Application to Evaluate Cruzain Inhibitory Activity by Chalcones and Hydrazides. Letters in Drug Design and Discovery, 11, 249-255.
Blau, L., Menegon, R.F., Trossini, G.H.G., Molino, J.V.D., Vital, D.G., Cicarelli, R.M.B., et al. (2013). Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates. European Journal of Medicinal Chemistry, 67, 142-151.
You can view some of Dr Drielli’s work below and links to her professional profile.
Orcid: https://orcid.org/0000-0001-9270-0466
Research Gate: https://www.researchgate.net/profile/Drielli-Gomes-Vital-Fujii
Scopus: https://www.scopus.com/authid/detail.uri?authorId=55829534000
Google Scholar: https://scholar.google.com/citations?user=F9U50AEAAAAJ&hl=pt-BR
Linkedin: linkedin.com/in/driellivital
Escavador: https://www.escavador.com/sobre/6101380/drielli-gomes-vital
CDIPD: https://cdipd.org/index.php/about-us/visiting-scientists
In this article, we will discuss whether Xanax affects kidneys, what research suggests, and what factors can affect kidney function while taking Xanax, precautions and guidelines for Xanax use to protect kidney function, and what to do if you are concerned about it.
Is Xanax bad for your kidneys?
Xanax is not necessarily bad for your kidneys. It is commonly prescribed for anxiety and panic disorders and belongs to the benzodiazepine class. The relationship between Xanax and kidney health has been a concern among healthcare professionals and patients.
However, it is important to note that very limited scientific research specifically links Xanax to kidney damage. Xanax acts on the central nervous system to relieve anxiety and is metabolized in the liver. So, it has a lower potential for direct kidney toxicity when compared to drugs primarily cleared through the kidneys.
What does research suggest?
While there may be limited evidence directly linking Xanax to kidney damage, it is crucial to consider the broader context of benzodiazepine use. Some studies have suggested that long-term use of benzodiazepines, like Xanax, may be associated with an increased mortality rate in patients with chronic kidney disease. (1)
According to another study, the effect of a 1.0 mg dose of Xanax was compared between 14 people; half were dialysis-dependent kidney patients, and half were healthy individuals. The result showed that chronic kidney failure does not significantly affect Xanax clearance from the body. (2)
However, because these studies have many complicated variables, it is difficult to determine a clear association between Xanax and kidney impairment.
What factors can affect kidney function while taking Xanax?
When you are using Xanax, certain factors can affect kidney function:
- Dosage: High doses or long-term use of Xanax may increase the risk of kidney damage. It is essential to take Xanax at the same frequency and dosage as your healthcare professional prescribes.
- Drug Interactions: Xanax can interact with other medications that might affect kidney function. Discuss all your medications with your doctor to ensure there are no adverse interactions.
- Underlying health conditions: If you have pre-existing kidney problems or other health issues, it is crucial to consult with your healthcare provider. They can assess whether Xanax is suitable for you or recommend alternative treatments.
- Individual variability: Individual factors like genetics can also influence the effect of Xanax on kidney function. Some people are more susceptible to the side effects of this medication. (3)
What to do to protect kidney function while using Xanax?
To minimize the potential risks associated with Xanax and protect your kidney health, consider the following precautions and guidelines:
- Medical supervision: Always use Xanax under the supervision of a qualified healthcare professional. They can determine the appropriate dosage and duration for your specific condition.
- Regular monitoring: If you are prescribed Xanax for an extended period, regular check-ups and kidney function tests may be advisable to detect any changes early.
- Stay hydrated: Adequate hydration is essential for kidney health. Make sure you drink enough water daily and maintain a healthy diet.
- Avoid alcohol: Alcohol can interact with Xanax and increase its toxicity, which can stress your kidneys more. It’s best to abstain from these while taking Xanax. (4)
- Report side effects: If you experience any unusual symptoms, including changes in urination or any discomfort in the kidney area, contact your healthcare provider immediately.
What to do if Xanax is affecting your kidneys?
If you have concerns about the effect of Xanax on your kidneys, the first step is to discuss them with your healthcare provider. They can evaluate your situation and help you make informed decisions about your treatment plan.
It may involve lowering the dose of Xanax or exploring alternative treatments like mirtazapine, which has a different side effect profile than Xanax, to protect your kidney health. It is important to remember that the relationship between Xanax and kidney function is complex and may vary from person to person.
Conclusion
According to my knowledge and research, the link between Xanax and kidney health remains a topic of ongoing investigation. Medical guidance and regular monitoring are crucial when considering its use. I emphasize the importance of open communication with healthcare providers to ensure kidney health.
Was this helpful?
References
1.-
Winkelmayer, W., Mehta, J., & Wang, P. (2007). Benzodiazepine use and mortality of incident dialysis patients in the United States. Kidney International, 72(11), 1388-1393. https://www.sciencedirect.com/science/article/pii/S0085253815525787
2.-
Ochs HR, Greenblatt DJ, Labedzki L, Smith RB. Alprazolam kinetics in patients with renal insufficiency. J Clin Psychopharmacol. 1986 Oct;6(5):292-4. PMID: 3771810.
3.-
George TT, Tripp J. Alprazolam. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538165/
4.-
Huang Z, Xu Z, Wang H, Zhao ZQ, Rao Y. Influence of ethanol on the metabolism of alprazolam. Expert Opin Drug Metab Toxicol. 2018 Jun;14(6):551-559. doi: 10.1080/17425255.2018.1483338. PMID: 29848078. https://pubmed.ncbi.nlm.nih.gov/29848078/
